Recent Breast Cancer News

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer

(December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual... Continue Reading


Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

(December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented... Continue Reading


Choice of surgery may affect quality of life for young breast cancer survivors

(December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research... Continue Reading


20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer

(October 31, 2018)

Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to... Continue Reading


More women with early-stage breast cancer may be able to avoid chemotherapy

(October 10, 2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had... Continue Reading


What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer?

(July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion... Continue Reading


FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

(July 23, 2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor... Continue Reading


Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

(July 9, 2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to... Continue Reading


U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation

(June 21, 2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA... Continue Reading


Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer

(April 19, 2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant... Continue Reading


Next Page »